Arvinas (ARVN) to Release Earnings on Thursday

Arvinas (NASDAQ:ARVN - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Arvinas to post earnings of ($0.93) per share and revenue of $41.87 million for the quarter.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the company earned ($0.97) EPS. The firm's quarterly revenue was up 646.2% compared to the same quarter last year. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Trading Up 6.8 %

Shares of ARVN traded up $0.49 during midday trading on Friday, hitting $7.72. 8,593,139 shares of the company's stock traded hands, compared to its average volume of 1,247,682. The firm's fifty day moving average is $9.66 and its 200-day moving average is $17.51. Arvinas has a 1 year low of $5.94 and a 1 year high of $37.38. The stock has a market capitalization of $530.92 million, a price-to-earnings ratio of -2.79 and a beta of 2.30.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ARVN shares. BMO Capital Markets set a $20.00 target price on shares of Arvinas and gave the stock an "outperform" rating in a research report on Wednesday, March 12th. Truist Financial decreased their target price on Arvinas from $65.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Citigroup cut their price target on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating on the stock in a report on Friday, March 7th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $10.00 price objective (down from $52.00) on shares of Arvinas in a report on Friday. Finally, Wedbush cut shares of Arvinas from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $25.82.

Insider Buying and Selling

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,230 shares of company stock worth $769,402. Insiders own 5.23% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.